The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 11, 2018

Filed:

Sep. 01, 2015
Applicants:

Heinrich-pette-institut Leibniz-institut Für Experimentelle Virologie-stiftung Bürgerlichen Rechts, Hamburg, DE;

Technische Universität Dresden, Dresden, DE;

Inventors:

Joachim Hauber, Hamburg, DE;

Jan Chemnitz, Oederquar, DE;

Frank Buchholz, Dresden, DE;

Janet Karpinski, Dresden, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 9/12 (2006.01); C12N 1/20 (2006.01); C12N 15/00 (2006.01); C07H 21/04 (2006.01); C12P 21/06 (2006.01); C12P 21/04 (2006.01); C12N 9/22 (2006.01); C12N 15/10 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C12N 9/1241 (2013.01); C12N 9/22 (2013.01); C12N 15/1058 (2013.01); A61K 38/00 (2013.01);
Abstract

The present invention relates to a method for preparing an expression vector encoding a well-tolerated and highly specific tailored recombinase, which tailored recombinase is capable of recombining asymmetric target sequences within the long terminal repeat (LTR) of proviral DNA of a plurality of retrovirus strains which may be inserted into the genome of a host cell, as well as to the obtained expression vector, cells transfected with these, expressed recombinase and pharmaceutical compositions comprising the expression vector, cells and/or recombinase. Pharmaceutical compositions are useful, e.g., in treatment and/or prevention of retrovirus infection, in particular, HIV infection. In particular, the invention relates to well-tolerated and highly specific tailored recombinases capable of combining asymmetric target sequences in a more than 90% of HIV-strains, thereby excising the HIV-1 sequences, and expression vectors encoding them.


Find Patent Forward Citations

Loading…